Wockhardt says Himachal Pradesh drug regulator suspends product

MUMBAI Wed Apr 23, 2014 7:15pm IST

Related Topics

Stocks

   
Coal Mining In The Punjab

Coal Mining In The Punjab

In Choa Saidan Shah miners dig coal with crude pick axes and load it onto donkeys to be transported to the surface earning a team of 4 workers around $10 to be split between them.  Slideshow 

MUMBAI (Reuters) - Indian drugmaker Wockhardt Ltd, which has been hit by a slew of overseas regulatory rebukes due to poor production quality, said the regulator in Himachal Pradesh has suspended the manufacture and sale of a product.

The state's drug controller suspended the manufacture, sale or distribution of fixed dose combination of Dicyclomine Hydrochloride IP 10mg, Tramadol Hydrochloride IP 50mg and Acetamenophen IP 325mg, the company said in a statement on Wednesday.

Wockhardt did not give the reason for the suspension.

But Navneet Marwah, Himachal Pradesh's drug regulator, told Reuters that some of the chemicals which the company used in making a painkiller sold under the brandname of Spasmo Proxyvon Plus have been banned by the Indian government.

"We got some complaints from the consumers and acted on that," Marwah said. He said the state regulator has sent a report to the federal drug regulator and the suspension will remain in force until a decision by the federal agency.

Wockhardt said the product contributed less than 3 percent of the consolidated sales of the company in the financial year that ended on March 31. The company will appeal to the state government to revoke the suspension, it said.

Wockhardt has been barred from exporting drugs from some of its plants in India to the United States, its largest market, and Britain, in the last one year due to poor manufacturing quality.

(Reporting by Sumeet Chatterjee; Editing by Anupama Dwivedi)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

HCL Tech Results

HCL Tech Results

Q4 dollar revenue disappoints investors, shares fall  Full Article 

Fed Policy

Fed Policy

Fed presses forward with bond buying, cites uptick in inflation.  Full Article 

Q2 Profit Slips

Q2 Profit Slips

Samsung sees tough second half  Full Article 

Chinese Economy

Chinese Economy

China should set lower 2015 GDP growth target of 6.5-7 percent - IMF  Full Article 

Default Imminent

Default Imminent

Argentina fails to reach debt agreement   Full Article 

Economy Reboots

Economy Reboots

U.S. economy back on track with strong second-quarter rebound  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage